IPCS INCHEM Home


    UNITED NATIONS ENVIRONMENT PROGRAMME
    INTERNATIONAL LABOUR ORGANISATION
    WORLD HEALTH ORGANIZATION


    INTERNATIONAL PROGRAMME ON CHEMICAL SAFETY



    ENVIRONMENTAL HEALTH CRITERIA 211





    HEALTH EFFECTS OF INTERACTIONS BETWEEN TOBACCO 
    USE AND EXPOSURE TO OTHER AGENTS





    This report contains the collective views of an international group of
    experts and does not necessarily represent the decisions or the stated
    policy of the United Nations Environment Programme, the International
    Labour Organisation, or the World Health Organization.

    Environmental Health Criteria  211

    First draft prepared by Dr K. Rothwell, Knaresborough, Yorkshire,
    United Kingdom

    Published under the joint sponsorship of the United Nations
    Environment Programme, the International Labour Organisation, and the
    World Health Organization, and produced within the framework of the
    Inter-Organization Programme for the Sound Management of Chemicals.



    World Health Organization
    Geneva, 1999



    The International Programme on Chemical Safety (IPCS), established in
    1980, is a joint venture of the United Nations Environment Programme
    (UNEP), the International Labour Organisation (ILO), and the World
    Health Organization (WHO).  The overall objectives of the IPCS are to
    establish the scientific basis for assessment of the risk to human
    health and the environment from exposure to chemicals, through
    international peer review processes, as a prerequisite for the
    promotion of chemical safety, and to provide technical assistance in
    strengthening national capacities for the sound management of
    chemicals.

    The Inter-Organization Programme for the Sound Management of Chemicals
    (IOMC) was established in 1995 by UNEP, ILO, the Food and Agriculture
    Organization of the United Nations, WHO, the United Nations Industrial
    Development Organization, the United Nations Institute for Training
    and Research, and the Organisation for Economic Co-operation and
    Development (Participating Organizations), following recommendations
    made by the 1992 UN Conference on Environment and Development to
    strengthen cooperation and increase coordination in the field of
    chemical safety.  The purpose of the IOMC is to promote coordination
    of the policies and activities pursued by the Participating
    Organizations, jointly or separately, to achieve the sound management
    of chemicals in relation to human health and the environment.

    WHO Library Cataloguing-in-Publication Data

    Health effects of interactions between tobacco use and exposure to
    other agents.

         (Environmental health criteria ; 211)

         1.Smoking - adverse effects  2.Tobacco smoke pollution  
         3.Drug interactions 4.Environmental exposure   
         5.Occupational exposure  6.Risk factors
         I.International Programme on Chemical Safety  II.Series

         ISBN 92 4 157211 6      (NLM Classification: QV 137)
         ISSN 0250-863X

    The World Health Organization welcomes requests for permission to
    reproduce or translate its publications, in part or in full. 
    Applications and enquiries should be addressed to the Office of
    Publications, World Health Organization, Geneva, Switzerland, which
    will be glad to provide the latest information on any changes made to
    the text, plans for new editions, and reprints and translations
    already available.

              (c) World Health Organization 1999

    Publications of the World Health Organization enjoy copyright
    protection in accordance with the provisions of Protocol 2 of the
    Universal Copyright Convention.  All rights reserved.

    The designations employed and the presentation of the material in this
    publication do not imply the expression of any opinion whatsoever on
    the part of the Secretariat of the World Health Organization
    concerning the legal status of any country, territory, city, or area
    or of its authorities, or concerning the delimitation of its frontiers
    or boundaries.

    The mention of specific companies or of certain manufacturers'
    products does not imply that they are endorsed or recommended by the
    World Health Organization in preference to others of a similar nature
    that are not mentioned. Errors and omissions excepted, the names of
    proprietary products are distinguished by initial capital letters.

    CONTENTS


    HEALTH EFFECTS OF INTERACTIONS BETWEEN TOBACCO USE AND EXPOSURE TO
    OTHER AGENTS


    PREAMBLE

    ABBREVIATIONS

    1. OVERVIEW

         1.1. Introduction
         1.2. Examples of combined effects of tobacco smoking and other
              exposures
         1.3. Composition of tobacco leaf and tobacco smoke
         1.4. Mainstream tobacco smoke
         1.5. Sidestream tobacco smoke
         1.6. Effects of ways of cigarette smoking on smoke
              toxicity
         1.7. Summary of conclusions and recommendations

    2. EXPOSURE TO TOBACCO PRODUCTS AND HEALTH RISKS FROM TOBACCO USE

         2.1. Tobacco and its uses
              2.1.1. Introduction
              2.1.2. Tobacco smoking
              2.1.3.    Tobacco chewing and snuff
         2.2. Responses to mainstream smoke
              2.2.1. Acute responses
                        2.2.1.1   Acute bronchitis
                        2.2.1.2   Asthma
              2.2.2. Chronic responses
                        2.2.2.1   Chronic obstructive lung
                                  diseases (COLD)
                        2.2.2.2   Chronic bronchitis
                        2.2.2.3   Small airways disease
                        2.2.2.4   Emphysema
                        2.2.2.5   Pulmonary fibrosis
                        2.2.2.6   Effects on the immune system
              2.2.3. Cancer
              2.2.4. Cardiovascular effects
              2.2.5. Smoking and occupational accidents, injuries and
                        absenteeism
         2.3. Health risks from smokeless tobacco use
              2.3.1. Introduction
              2.3.2. Cancer
              2.3.3. Cardiovascular disease

    3. EFFECTS ON HEALTH OF TOBACCO USE AND EXPOSURE TO OTHER CHEMICALS

         3.1. Introduction
              3.1.1. Interaction
              3.1.2. Measuring interaction
              3.1.3. Effects of tobacco smoking on lung deposition 
                        and clearance of particles
         3.2. Interactions between tobacco smoke and other agents
              3.2.1. Asbestos
                        3.2.1.1   Asbestos and lung cancer
                        3.2.1.2   Asbestos and pleural
                                  mesothelioma
                        3.2.1.3   Asbestos and other forms of cancer
                        3.2.1.4   Asbestosis
         3.3. Non-asbestos fibres
              3.3.1. Glass fibre
              3.3.2. Rockwool, slagwool and ceramic fibres
         3.4. Inorganic chemicals
              3.4.1. Arsenic
              3.4.2. Beryllium
              3.4.3. Chromium
              3.4.4. Nickel
              3.4.5. Manganese
              3.4.6. Platinum
              3.4.7. Silica
         3.5. Organic chemical agents
              3.5.1. Chloromethyl ethers
              3.5.2. Tetrachlorophthalic anhydride
              3.5.3. Dyestuffs
              3.5.4. Polycyclic aromatic hydrocarbons
              3.5.5. Ethanol
              3.5.6. Other organic compounds
         3.6. Physical agents
              3.6.1. Radiation
                        3.6.1.1   Radon in mines (high linear energy
                                  transfer (LET) alpha-radiation)
                        3.6.1.2   Environmental radon (high linear
                                  energy transfer (LET) alpha-radiation)
                        3.6.1.3   Atomic bomb site radiation
                                  (low linear energy transfer (LET)
                                  radiation)
                        3.6.1.4   Therapeutic X-rays (low linear
                                  energy transfer (LET) radiation)
                        3.6.1.5   Nuclear plant
                        3.6.1.6   Summary
              3.6.2. Vibration
              3.6.3. Noise
              3.6.4. Dupuytren's contracture
         3.7. Biological agents
              3.7.1. Biological (vegetable) dusts
                        3.7.1.1   Cotton dust
                        3.7.1.2   Wood dust
                        3.7.1.3   Allergic responses

              3.7.2. Other biological agents
              3.7.3. Agents found in factory farming
                        (animal confinement effects)
              3.7.4. Laboratory animals
              3.7.5. Schistosomiasis
              3.7.6. Other urinary tract infections
              3.7.7. Sarcoidosis
         3.8. Vector effects
              3.8.1. Polytetrafluoroethylene
              3.8.2. Mercury
         3.9. Effects of tobacco smoking and metabolism
              of drugs and other chemicals
              3.9.1. Oral contraceptive use
              3.9.2. Drug and chemical metabolism
         3.10. Animal studies of the interactions between
              cigarette smoke exposure and other agents
              3.10.1. Non-cancer end-points
              3.10.2. Cancer studies: tobacco (cigarette)
                        smoke plus other chemicals
              3.10.3. Cancer studies: cigarette smoke plus
                        radiation

    4. EFFECTS OF EXPOSURE TO TOBACCO SMOKE AND OTHER AGENTS: SEPARATE
         EFFECTS OR POSSIBLE INTERACTIONS

         4.1. Coal mining
              4.1.1. Coal dust
              4.1.2. Bronchitis in coal miners
              4.1.3. Emphysema and pneumoconiosis in coal miners
              4.1.4. Lung cancer in coal miners
         4.2. Other mineral dusts
              4.2.1. Talc
              4.2.2. Kaolin
              4.2.3. Alumina
         4.3. Fibrous minerals
         4.4. Metals
              4.4.1. Antimony
              4.4.2. Cadmium
              4.4.3. Cobalt
              4.4.4. Lead
         4.5. Rubber industry
         4.6. Petroleum industry
         4.7. Pesticides

    5. CONCLUSIONS AND RECOMMENDATIONS

         5.1. Conclusions
         5.2. Recommendations for protection of human health

    6. FURTHER RESEARCH

         REFERENCES

         SYNOPSIS

         PANORAMA GENERAL
    

    NOTE TO READERS OF THE CRITERIA MONOGRAPHS

    Every effort has been made to present information in the criteria
    monographs as accurately as possible without unduly delaying their
    publication.  In the interest of all users of the Environmental Health
    Criteria monographs, readers are requested to communicate any errors
    that may have occurred to the Director of the International Programme
    on Chemical Safety, World Health Organization, Geneva, Switzerland, in
    order that they may be included in corrigenda.



                               *     *     *



    A detailed data profile and a legal file can be obtained from the
    International Register of Potentially Toxic Chemicals, Case postale
    356, 1219 Chātelaine, Geneva, Switzerland (telephone no. + 41 22 
    - 9799111, fax no. + 41 22 - 7973460, E-mail irptc@unep.ch).



                               *     *     *



    This publication was made possible by grant number 5 U01 ES02617-15
    from the National Institute of Environmental Health Sciences, National
    Institutes of Health, USA, and by financial support from the European
    Commission.

    Environmental Health Criteria

    PREAMBLE

    Objectives

    In 1973 the WHO Environmental Health Criteria Programme was initiated
    with the following objectives:

    (i)       to assess information on the relationship between exposure
              to environmental pollutants and human health, and to provide
              guidelines for setting exposure limits;

    (ii)      to identify new or potential pollutants;

    (iii)     to identify gaps in knowledge concerning the health effects
              of pollutants;

    (iv)      to promote the harmonization of toxicological and 
              epidemiological methods in order to have internationally 
              comparable results.

    The first Environmental Health Criteria (EHC) monograph, on mercury,
    was published in 1976 and since that time an ever-increasing number of
    assessments of chemicals and of physical effects have been produced. 
    In addition, many EHC monographs have been devoted to evaluating
    toxicological methodology, e.g., for genetic, neurotoxic, teratogenic
    and nephrotoxic effects.  Other publications have been concerned with
    epidemiological guidelines, evaluation of short-term tests for
    carcinogens, biomarkers, effects on the elderly and so forth.

    Since its inauguration the EHC Programme has widened its scope, and
    the importance of environmental effects, in addition to health
    effects, has been increasingly emphasized in the total evaluation of
    chemicals.

    The original impetus for the Programme came from World Health Assembly
    resolutions and the recommendations of the 1972 UN Conference on the
    Human Environment.  Subsequently the work became an integral part of
    the International Programme on Chemical Safety (IPCS), a cooperative
    programme of UNEP, ILO and WHO.  In this manner, with the strong
    support of the new partners, the importance of occupational health and
    environmental effects was fully recognized. The EHC monographs have
    become widely established, used and recognized throughout the world.

    The recommendations of the 1992 UN Conference on Environment and
    Development and the subsequent establishment of the Intergovernmental
    Forum on Chemical Safety with the priorities for action in the six
    programme areas of Chapter 19, Agenda 21, all lend further weight to
    the need for EHC assessments of the risks of chemicals.

    Scope

    The criteria monographs are intended to provide critical reviews on
    the effect on human health and the environment of chemicals and of
    combinations of chemicals and physical and biological agents.  As
    such, they include and review studies that are of direct relevance for
    the evaluation.  However, they do not describe  every study carried
    out.  Worldwide data are used and are quoted from original studies,
    not from abstracts or reviews.  Both published and unpublished reports
    are considered and it is incumbent on the authors to assess all the
    articles cited in the references.  Preference is always given to
    published data.  Unpublished data are only used when relevant
    published data are absent or when they are pivotal to the risk
    assessment.  A detailed policy statement is available that describes
    the procedures used for unpublished proprietary data so that this
    information can be used in the evaluation without  compromising its
    confidential nature (WHO (1990) Revised Guidelines for the Preparation
    of Environmental Health Criteria Monographs. PCS/90.69, Geneva, World
    Health Organization).

    In the evaluation of human health risks, sound human data, whenever
    available, are preferred to animal data.  Animal and  in vitro
    studies provide support and are used mainly to supply evidence missing
    from human studies.  It is mandatory that research on human subjects
    is conducted in full accord with ethical principles, including the
    provisions of the Helsinki Declaration.

    The EHC monographs are intended to assist national and international
    authorities in making risk assessments and subsequent risk management
    decisions.  They represent a thorough evaluation of risks and are not,
    in any sense, recommendations for regulation or standard setting. 
    These latter are the exclusive purview of national and regional
    governments.

    Content

    The layout of EHC monographs for chemicals is outlined below.

    *    Summary -- a review of the salient facts and the risk evaluation
         of the chemical
    *    Identity -- physical and chemical properties, analytical methods
    *    Sources of exposure
    *    Environmental transport, distribution and transformation
    *    Environmental levels and human exposure
    *    Kinetics and metabolism in laboratory animals and humans
    *    Effects on laboratory mammals and  in vitro test systems
    *    Effects on humans
    *    Effects on other organisms in the laboratory and field
    *    Evaluation of human health risks and effects on the environment
    *    Conclusions and recommendations for protection of human health
         and the environment

    *    Further research
    *    Previous evaluations by international bodies, e.g., IARC, JECFA,
         JMPR

    Selection of chemicals

    Since the inception of the EHC Programme, the IPCS has organized
    meetings of scientists to establish lists of priority chemicals for
    subsequent evaluation.  Such meetings have been held in: Ispra, Italy,
    1980; Oxford, United Kingdom, 1984; Berlin, Germany, 1987; and North
    Carolina, USA, 1995. The selection of chemicals has been based on the
    following criteria: the existence of scientific evidence that the
    substance presents a hazard to human health and/or the environment;
    the possible use, persistence, accumulation or degradation of the
    substance shows that there may be significant human or environmental
    exposure; the size and nature of populations at risk (both human and
    other species) and risks for environment; international concern, i.e.
    the substance is of major interest to several countries; adequate data
    on the hazards are available.

    If an EHC monograph is proposed for a chemical not on the priority
    list, the IPCS Secretariat consults with the Cooperating Organizations
    and all the Participating Institutions before embarking on the
    preparation of the monograph.

    Procedures

    The order of procedures that result in the publication of an EHC
    monograph is shown in the flow chart.  A designated staff member of
    IPCS, responsible for the scientific quality of the document, serves
    as Responsible Officer (RO).  The IPCS Editor is responsible for
    layout and language.  The first draft, prepared by consultants or,
    more usually, staff from an IPCS Participating Institution, is based
    initially on data provided from the International Register of
    Potentially Toxic Chemicals, and reference data bases such as Medline
    and Toxline.

    The draft document, when received by the RO, may require an initial
    review by a small panel of experts to determine its scientific quality
    and objectivity.  Once the RO finds the document acceptable as a first
    draft, it is distributed, in its unedited form, to well over 150 EHC
    contact points throughout the world who are asked to comment on its
    completeness and accuracy and, where necessary, provide additional
    material.  The contact points, usually designated by governments, may
    be Participating Institutions, IPCS Focal Points, or individual
    scientists known for their particular expertise.  Generally some four
    months are allowed before the comments are considered by the RO and
    author(s).  A second draft incorporating comments received and
    approved by the  Director, IPCS, is then  distributed to Task Group
    members, who carry out the peer review, at least six weeks before
    their meeting.

    The Task Group members serve as individual scientists, not as
    representatives of any organization, government or industry.  Their
    function is to evaluate the accuracy, significance and relevance of
    the information in the document and to assess the health and
    environmental risks from exposure to the chemical.  A summary and
    recommendations for further research and improved safety aspects are
    also required.  The composition of the Task Group is dictated by the 
    range of expertise required for the subject of the meeting and by the 
    need for a balanced geographical distribution.

    The three cooperating organizations of the IPCS recognize the
    important role played by nongovernmental organizations.
    Representatives from relevant national and international associations
    may be invited to join the Task Group as observers.  While observers
    may provide a valuable contribution to the process, they can only
    speak at the invitation of the Chairperson. Observers do not
    participate in the final evaluation of the chemical; this is the sole
    responsibility of the Task Group members.  When the Task Group
    considers it to be appropriate, it may meet  in camera.

    All individuals who as authors, consultants or advisers participate in
    the preparation of the EHC monograph must, in addition to serving in
    their personal capacity as scientists, inform the RO if at any time a
    conflict of interest, whether actual or potential, could be perceived
    in their work.  They are required to sign a conflict of interest
    statement. Such a procedure ensures the transparency and probity of
    the process.

    When the Task Group has completed its review and the RO is satisfied
    as to the scientific correctness and completeness of the document, it
    then goes for language editing, reference checking, and preparation of
    camera-ready copy.  After approval by the Director, IPCS, the
    monograph is submitted to the WHO Office of Publications for printing. 
    At this time a copy of the final draft is sent to the Chairperson and
    Rapporteur of the Task Group to check for any errors.

    It is accepted that the following criteria should initiate the
    updating of an EHC monograph: new data are available that would
    substantially change the evaluation; there is public concern for
    health or environmental effects of the agent because of greater
    exposure; an appreciable time period has elapsed since the last
    evaluation.

    All Participating Institutions are informed, through the EHC progress
    report, of the authors and institutions proposed for the drafting of
    the documents.  A comprehensive file of all comments received on
    drafts of each EHC monograph is maintained and is available on
    request.  The Chairpersons of Task Groups are briefed before each
    meeting on their role and responsibility in ensuring that these rules
    are followed.

    FIGURE 


    WHO WORKING GROUP ON HEALTH RISKS FROM THE COMBINED EFFECTS OF TOBACCO
    SMOKING AND EXPOSURE TO OTHER CHEMICALS

    (Geneva, 25-26 April 1966)

     Members

    Dr G. Finch, Inhalation Toxicology Research Institute, Lovelace
         Biomedical and Environmental Research Institute, Albuquerque, New
         Mexico, USA

    Professor G. Pershagen, Division of Epidemiology, Institute of
         Environmental Medicine, Karolinska Institute, Stockholm, Sweden

    Dr K. Rothwell, Knaresborough, Yorkshire, United Kingdom

    Professor H.-P. Witschi, Institute of Toxicology and Environmental
         Health, University of California, Davis, California, USA


     Secretariat

    Dr E. Smith, International Programme on Chemical Safety, World
         Health Organization, Geneva, Switzerland

    Mr N.F. Collishaw, Tobacco or Health, Programme on Substance
         Abuse, World Health Organization, Geneva, Switzerland


    WHO TASK GROUP ON HEALTH EFFECTS OF INTERACTIONS BETWEEN TOBACCO USE
    AND EXPOSURE TO OTHER AGENTS

    (Geneva, 18-21 February 1997)


     Members

    Dr G. Finch, Lovelace Respiratory Research Institute, Inhalation
         Toxicology Research Institute, Albuquerque, New Mexico, USA 
         ( Chairman)

    Dr L. Fishbein, Fairfax, VA, USA ( Joint Rapporteur)

    Dr Dorota Jarosinska, Institute of Occupational Medicine and
         Environmental Health, Sosnowiec, Poland

    Professor G. Kazantzis, Royal School of Mines, London, United
         Kingdom ( Joint Rapporteur)

    Professor U. Keil, Institute for Epidemiology and Social Medicine,
         Münster, Germany

    Dr D. Krewski, Environmental Health Directorate, Health Canada,
         Ottawa, Ontario, Canada

    Dr K. Rothwell, Knaresborough, Yorkshire, United Kingdom
         ( Vice-Chairman)

    Dr L. van Bree, Laboratory of Health Effects Research, National
         Institute of Public Health and the Environment, Bilthoven, The
         Netherlands


     Observers

    Dr G. Minotti, Catholic University of the Sacred Heart, Rome, Italy
         ( representing the International Union of Pharmaceutical
         Societies)

     Secretariat

    Dr E. Smith, International Programme on Chemical Safety, World
         Health Organization, Geneva, Switzerland ( Secretary)

    Mrs B.F. Goelzer, Occupational Health, World Health Organization,
         Geneva, Switzerland

    Mr N.E. Collishaw, Programme on Substance Abuse, World Health
         Organization, Geneva, Switzerland

    HEALTH EFFECTS OF INTERACTIONS BETWEEN TOBACCO USE AND EXPOSURE TO
    OTHER AGENTS

    A WHO Task Group on Health Effects of Interactions Between Tobacco Use
    and Exposure to Other Agents met at the World Health Organization,
    Geneva, from 18 to 21 February 1997. Dr E. Smith, IPCS, welcomed the
    participants on behalf of Dr M. Mercier, Director IPCS, and the
    cooperating organizations. The Task Group reviewed and revised the
    draft monograph and developed a new text.

    The first draft of the monograph was prepared by Dr K. Rothwell,
    Knaresborough, Yorkshire, United Kingdom. This draft was further
    developed by a Working Group held in WHO, Geneva, 25-26 April 1996,
    and then circulated for international comment to IPCS contact points
    for  Environmental Health Criteria monographs. Comments were
    incorporated in a second draft prepared by Dr K. Rothwell. This draft
    was reviewed at the Task Group meeting and a text given further
    limited circulation to Task Group members and a number of other
    experts, including the US EPA National Center for Environmental
    Assessment under the coordination of Dr D. Mukerjee, for final
    comment. In the development of the monograph, contributions were made
    by a number of authors listed below.

    Dr E. Smith (IPCS Unit for the Assessment of Risk and Methods) was
    responsible for the scientific content of the monograph and Dr P.G.
    Jenkins (IPCS Central Unit) for the technical editing.

    The efforts of all who helped in the preparation and finalization of
    the monograph are gratefully acknowledged.

         The authors were:

    Main authors

    Dr K. Rothwell, Knaresborough, Yorkshire, United Kingdom
         ( Coordinating author)

    Dr G. Finch, Lovelace Respiratory Research Institute, Albuquerque,
         New Mexico, USA

    Dr L. Fishbein, Fairfax, Virginia, USA

    Dr D. Krewski, Environmental Health Directorate, Health Canada,
         Ottawa, Ontario, Canada

    Professor G. Pershagen, Institute of Environmental Medicine,
         Karolinska Institute, Stockholm, Sweden

    Professor H-P. Witschi, Institute of Toxicology and Environmental
         Health, University of California, Davis, California, USA

    Contributing authors

    Dr D. Jarosinska, Institute of Occupational Medicine and
         Environmental Health, Sosnowiec, Poland

    Professor G. Kazantzis, Royal School of Mines, London, United
         Kingdom

    Professor U. Keil, Institute for Epidemiology and Social Medicine,
         Munster, Germany

    Dr E. Smith, International Programme on Chemical Safety, World
         Health Organization, Geneva, Switzerland

    Dr L. van Bree, National Institute of Public Health and the
         Environment, Bilthoven, the Netherlands

                                       * * *

    The IPCS expresses its gratitude to the external reviewers who
    provided comments and other relevant material, in particular the
    United Kingdom Department of Health, London, and the US Environmental
    Protection Agency's Office of Research and Development, National
    Center for Environmental Assessment, Cincinnati, Ohio, USA.

    The funds for the preparation, review and publication of this
    monograph were generously provided by Health Canada.

    ABBREVIATIONS


    BCME    bis(chloromethyl) ether
    CMME    chloromethyl methyl ether
    COLD    chronic obstructive lung disease
    CHD     coronary heart disease
    CVD     cardiovascular disease
    ERR     excess relative risk
    FIV1    forced expiratory volume (1 second)
    IARC    International Agency for Research on Cancer
    LET     linear energy transfer
    MMAD    mass median aerodynamic diameter
    NOx     nitrogen oxides
    SAD     small airways disease
    TSNA    tobacco-specific nitroasamines
    URT     upper respiratory tract

    1.  OVERVIEW

    1.1  Introduction

    Tobacco use, particularly smoking, causes a range of adverse health
    effects, is directly implicated in a number of serious diseases, and
    can increase adverse effects of other chemical, physical and
    biological agents. Chemicals and other agents in workplaces can cause,
    if not controlled, disease, incapacity and early death. In the
    workplace it is clear that adverse effects can be produced by the
    synergistic interaction of tobacco smoking and other hazards. The
    majority of interactions of harmful tobacco smoke constituents with
    toxic chemicals occur when the latter are airborne, although
    interactions of smoking with ingested and/or absorbed harmful agents
    have also been reported.

    Tobacco use is widespread throughout the world, from countries with
    low income economies to the most affluent industrialized nations.
    Tobacco is used by men and women, by children and adults, and millions
    of people are involuntarily subjected to environmental tobacco smoke.
    There are numerous explanations for the tobacco habit but the main
    reason for its ubiquity is the addictive drug nicotine present in all
    forms of tobacco leaf and delivered in varying amounts to the user by
    the various methods of tobacco use (chapter 2). The advent of the
    cigarette, mass produced, easily obtainable, relatively cheap and
    light in weight, so it can be held in the mouth leaving the hands
    free, has had a major impact on smoking habits, in general and in
    workplaces.

    In many countries tobacco smoking is recognized as a serious health
    hazard and a major contributing factor to deaths from a number of
    common diseases. In these countries health warning legislation and
    measures to control consumption by taxation have been implemented, as
    well as public education programmes on the dangers of smoking and the
    benefits to be gained from not starting or from stopping. However,
    there are still countries where decisive action has yet to be taken to
    deal with the problem of tobacco use.

    Many work situations involve an element of risk. The nature of the
    work may generate harmful effects on health, and working activities
    may cause environmental contamination. Tobacco growing itself involves
    the use of pesticides, harvesting of tobacco leaf can cause sickness
    due to skin absorption of nicotine, and processing exposes workers to
    health hazards from airborne dust and fungal spores. A high male
    cancer incidence has been reported in areas with tobacco industries.
    In mining there are airborne mineral dusts and, in farming and
    industries using biologically produced raw materials, biological dusts
    are found. Fumes are produced during welding, and gases, smokes, mists
    and vapours containing inorganic and/or organic toxic substances
    present hazards in many industries. Excessive heat or exposure to
    ultraviolet light can be detrimental to the well-being of workers.
    Ionizing radiation in mining and modern technology is recognized as a
    workplace hazard. In many occupations workers are subjected to

    excessive noise or harmful mechanical vibration. Working conditions
    can impact adversely on health to a greater extent in smokers than
    non-smokers. In many countries, smoking at the workplace is 
    prohibited, primarily for reasons of fire/explosion safety. However, 
    in some countries, regulations are not always enforced. In some newly 
    industrializing countries health problems associated with work have 
    not yet been fully addressed and many employers and workers are 
    ignorant of the dangers to health of their occupations. In addition, 
    there is the large "informal sector" of industry, particularly in 
    developing countries, where the home is the workplace, chemicals are 
    used (including solvents, resins, and synthetic dyestuffs), the whole 
    family is exposed, and there are no restrictions on exposure to work
    hazards or smoking.

    The situation for adverse health effects resulting from combined
    exposure to tobacco smoke, mainstream or environmental, and agents in
    the domestic environment is much less defined. However, the incidence
    of lung cancer and the concentration of radon in homes has a similar
    dose-response to lung cancer and radon in mines, and the risk is
    higher in smokers.

    1.2  Examples of combined effects of tobacco smoking and other
         exposures

    There is evidence for synergism in the production of adverse effects
    (cancer) between tobacco smoking and exposure to arsenic, asbestos,
    ethanol, silica and radiation (radon, atomic bomb, X-ray). On the
    other hand there is evidence for antagonism in the case of tobacco
    smoking and the carcinogenic chloromethyl ethers, i.e. chloromethyl
    methyl ether (CMME) and bis(chloromethyl) ether (BCME) (Hoffmann &
    Wynder, 1976; IARC, 1986), tobacco smoking and allergic alveolitis,
    and tobacco smoking and chronic beryllium disease. Tobacco smoking
    affects the health risks of exposures in coal mining, pesticide
    handling, and in the rubber and petroleum industries. Coal miners who
    smoke are at greater risk of developing chronic bronchitis and
    obstructive airway disease but not emphysema. Lung cancer in coal
    miners has been attributed entirely to tobacco smoking. Tobacco
    smoking can increase the health risks of exposure to vegetable dusts
    that produce chronic respiratory conditions, such as byssinosis
    produced by cotton dust, and nasal cancer caused by wood dusts.

    1.3  Composition of tobacco leaf and tobacco smoke

    More than 3040 chemical compounds have been isolated from processed
    tobacco leaf (Roberts, 1988). Most are leaf constituents, but some
    arise from growing conditions such as the soil and atmosphere in an
    area, while others originate from the use of agricultural chemicals,
    from casings, humectants and flavourings added to the leaves, and from
    curing methods. Different tobacco varieties grown in different
    countries, and cured and processed in various ways show differences.
    The proportions of individual constituents may differ but not the
    overall composition. Among important toxic compounds identified, other
    than nicotine, are carcinogenic nitrosamines, derived from nitrites,

    amines, proteins and alkaloids present in the leaf, polycyclic
    aromatic hydrocarbons resulting from the curing process, radioactive
    elements absorbed from the soil and the air, and cadmium in tobacco
    grown on cadmium-rich soils. When tobacco is burned in the course of
    smoking, many pyrolysis and other reaction products are formed.

    1.4  Mainstream tobacco smoke

    Tobacco smoke is an aerosol consisting of a particulate phase of
    liquid droplets dispersed in a gas/vapour phase. When a cigarette is
    smoked, many compounds are formed by pyrolysis of the tobacco. These
    either pass through the cigarette as mainstream smoke, some being
    condensed a short distance behind the burning cone, or they are
    emitted into the air from the burning end as sidestream smoke. With
    each puff the smoke becomes progressively stronger because previously
    condensed material is added to the smoke and the length of cigarette
    available for further condensation is decreasing. The physicochemical
    nature of the smoke depends on the processing and burning of the
    tobacco, the porosity and treatment of the paper wrapper, and on the
    type of filter tip (Hoffmann & Hoffmann, 1997). In the case of a
    cigarette or Asian "bidi" (tobacco wrapped in vegetable leaf), the
    smoke chemistry is affected by such factors as dimensions, wrapper
    porosity and the smoking parameters of puff volume, frequency and
    duration (NIH, 1998). Variations in smoke chemistry are mainly in the
    balance of smoke constituents rather than the presence or absence of
    particular compounds.

    Mainstream smoke is generated in a comparatively low-oxygen atmosphere
    at a burning temperature of 850-950°C in the fire cone. Initially,
    mainstream smoke particles have a mass median aerodynamic diameter
    (MMAD) of 0.2 to 0.3 µm; however, as soon as they encounter the 100%
    humidity of the respiratory tract, they coalesce into larger particles
    and behave as if their MMAD was in the micrometre range. Between 50
    and 90% of all inhaled particulate matter may be retained in the
    respiratory tract (Wynder & Hoffmann, 1967; Hinds et al., 1983). From
    size considerations, the aerosol particulate matter, the vapour phase
    constituents and the permanent gases are capable of reaching the
    alveoli when smoke is inhaled. Deposition in the tracheobronchial tree
    is complicated by the behaviour of hydrophilic constituents in the
    high humidity conditions, but smoke reaches every part of the airways.

    Mainstream smoke contains nearly 4000 identified chemicals and an
    unknown number of unidentified chemicals (Roberts, 1988). Mainstream
    smoke can be divided into particulate and gas phases. Mainstream smoke
    particulate phase contains nicotine, nitrosamines such as
    4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and
     N-nitrosonornicotine (NNN), metals such as cadmium, nickel, zinc and
    polonium-210, polycyclic hydrocarbons, and carcinogenic amines, such
    as 4-aminobiphenyl. The vapour phase contains carbon monoxide, carbon
    dioxide, benzene, ammonia, formaldehyde, hydrogen cyanide,
     N-nitrosodimethylamine,  N-nitrosodiethylamine and other compounds.
    Compounds in tobacco smoke can be classified by their biological
    activity as asphyxiants, irritants, ciliatoxins, mutagens,

    carcinogens, enzyme inhibitors, neurotoxins or pharmacologically
    active compounds. The main point of entry of cigarette smoke into the
    body is via the airways, but many constituents, particularly from pipe
    and cigar smoke, dissolve in saliva and are absorbed in the buccal
    cavity or are swallowed. Cigar and pipe smokers generally do not
    inhale the smoke and it remains in the oral cavity, is dissolved in
    the saliva and absorbed through the mucous membranes or swallowed
    (NIH, 1998). Alcoholic drinks have a solvent effect for the smoke
    constituents facilitating their absorption.

    1.5  Sidestream tobacco smoke

    Sidestream smoke is generated at lower burning temperature (500-600°C)
    in a reducing atmosphere. Fresh sidestream smoke particles are about
    the same size as mainstream smoke particles with a mass median
    aerodynamic diameter (MMAD) of approximately 0.2 µm. Qualitatively,
    sidestream smoke composition is similar to the composition of
    mainstream smoke. Some chemicals in sidestream smoke are emitted at
    higher concentrations per gram of tobacco burned than in mainstream
    smoke. This is particularly so for carcinogens such as
     N-nitrosodimethylamine and  N-nitrosodiethyl-amine, and for metals
    such as nickel or cadmium. Many carcinogenic compounds are more
    concentrated in sidestream than in mainstream smoke. Mouse
    skin-painting bioassays have shown that condensate of sidestream smoke
    is more carcinogenic than that of mainstream smoke (Wynder & Hoffmann,
    1967; US Surgeon General, 1986; NIH, 1998).

    1.6  Effects of ways of cigarette smoking on smoke toxicity

    The nicotine content of different cigarettes varies, and the smoker
    adjusts the smoking intensity and depth of inhalation to satisfy the
    acquired nicotine need. Consequently, the smoker of a filter cigarette
    with a low nicotine yield (<1.2 mg) smokes more intensively and this
    influences toxicity (NIH, 1998).

    1.7  Summary of conclusions and recommendations

    Tobacco use, particularly smoking, is a most important public health
    hazard and a major preventable cause of morbidity and mortality. In
    addition to the adverse health effects of active tobacco use, adverse
    health effects have been demonstrated to result from exposure to
    environmental tobacco smoke. The risks from tobacco smoking are also
    increased through interactions with certain chemical, physical and
    biological hazards found in the workplace and general environment.
    There are a few instances of antagonistic interactions, but the health
    risks of tobacco smoke far outweigh any apparent protective effects.

    All possible measures should be taken to eliminate tobacco use,
    particularly smoking, and smoking in public places should be strongly
    discouraged. To avoid interaction with occupational exposures and to
    eliminate the risk of exposure to environmental tobacco smoke, smoking
    in the workplace should be prohibited.

    To protect health, in particular that of children, smoking in domestic
    environments should be strongly discouraged. This will prevent
    possible harmful interactions between tobacco smoke and residential
    exposures to other hazards. There is a pressing need for educational
    programmes on the health hazards of smoking. Health professionals
    should provide assistance to help smokers quit. Since smoking may
    result in altered response or adverse reactions to drugs and other
    treatments, appropriate dose adjustments and patient surveillance
    should be taken into consideration by clinicians.
    

    2.  EXPOSURE TO TOBACCO PRODUCTS AND HEALTH RISKS FROM TOBACCO USE

    2.1  Tobacco and its uses

    2.1.1  Introduction

    The genus  Nicotiana, a member of the plant family  Solanaceae, is
    represented by about 100 species and sub-species (Cromwell, 1955; Tso,
    1990) widely distributed throughout the world. The species  N.
     tabacum and  N. rustica are the principal sources of tobacco. The
    primary intention in using tobacco is to obtain the alkaloid nicotine
    and, once the habit has been established, nicotine appears to fulfil
    both a pharmacological and psychological need (US Surgeon General,
    1988; NIH, 1998).

    Tobacco and its uses were unknown outside America before its discovery
    by Columbus. In a description of tobacco use in South America at that
    period, Wilbert (1987) used information from European explorers.

    There were six types of tobacco use: chewing, drinking, licking,
    rectal insertion, nasal and oral snuffing, and smoking. Smoking was by
    far the most common, while rectal application was only used
    occasionally. Tobacco smoke was inhaled via the mouth through tubes or
    rolls of tobacco leaf, or through the nostrils using a Y-shaped tube.
    Alternatively, it was swallowed and belched back, blown from one
    person to another, or blown into the eyes. Leaves were chewed, alone
    or mixed with ash, powdered shells or honey, or they were held in the
    mouth and sucked. Infusions were drunk or a concentrated infusion was
    licked or even used as an enema. Many ways of preparing and taking
    snuff among different tribes were reported. Tobacco use was linked to
    religious rituals.

    The rest of the world adopted tobacco use in the forms of smoking,
    chewing and snuffing. Smoking has remained the most popular. Tobacco
    smoking consists of burning the cured leaf, perhaps mixed with
    fragrant additives, in a pipe or tube. Cigarette smoking has largely
    replaced other methods in many countries. Reasons for the popularity
    of cigarettes include their ready availability resulting from
    large-scale manufacture and their greater convenience over other forms
    of tobacco use (IARC, 1986). In developed countries, cigarettes
    account for at least 80% of overall tobacco consumption, but in most
    developing countries other ways of using tobacco predominate, although
    cigarette smoking is increasing. Fig. 1 shows estimated daily
    cigarette consumption on a regional basis, Tables 1 and 2 show daily
    smoking prevalences on a regional and national basis and Table 3 shows
    trends in cigarette consumption.

    FIGURE 1

    2.1.2  Tobacco smoking

    Smoking prevalence data and most studies into the effects of smoking
    have concentrated on cigarette smoking, yet worldwide only about 55%
    of tobacco is used for cigarettes. The rest, along with significant
    amounts traded in "farm gate" and "local market" sales or "home
    grown", is smoked in "bidis" or other hand-rolled devices, or in some
    form of pipe (IARC, 1986). Tobacco consumption data give an insight
    into tobacco-related disease distribution, as can information on ways
    of smoking.

    Table 1.  Estimated smoking prevalence by WHO Region, early 1990s
    (from WHO, 1997)
                                                                     

                                              Men              Women
                                              (%)              (%)
                                                                     

    WHO Regions:
      African Regiona                         29               4
      Region of the Americas                  35               22
      Eastern Mediterranean Region            35               4
      European Region                         46               26
      South-East Asia Region                  44               4
      Western Pacific Region                  60               8
    More developed countries                  42               24
    Less developed countries                  48               7
    World                                     47               12
                                                                     

    a  Smoking prevalence estimates for African Region are based on
       very limited information

    Differences in smoke chemistry occur with different tobacco cultivars
    and curing methods. Curing removes moisture so that the leaf can be
    stored without fermenting or rotting, and the time and temperature of
    curing influences enzyme reactions such as deamination and oxidation,
    and the content of oils and resins. Air-, flue-, sun-, and fire-curing
    methods are employed and each produces distinctive tobaccos which are
    intended for smoking in a specific way or to suit a particular
    preference.

    Between 1933 and the late 1940s, the yields from an average cigarette
    varied from 33 to 49 mg tar and from < 1 to 3 mg nicotine (Creek et
    al., 1994). However, in the 1960s and 1970s, the average yield from
    cigarettes in Western Europe and the USA was around 16 mg tar and 1.5

    mg nicotine per cigarette. Current average levels are lower. Changes
    in the levels of tar and nicotine have resulted in the characteristic
    more intense puffing and smoke inhalation pattern of smokers of
    low-yield cigarettes (Djordjevic et al., 1995; NIH, 1996). The 
    high tar yields measured in the smoke of cigarettes in developed
    countries before 1950 are comparable with current tar yields of
    "bidis", which range from 23 to 48 mg per cigarette (Hoffmann et al.,
    1974; Jayant & Pakhale, 1985; Ball & Simpson, 1987.) The "kretek" (a
    cigarette of strong tobacco and cloves) of Indonesia yields up to
    71 mg tar (WHO, 1985). Smoking materials in northern Thailand
    (cigarette or cigar of strong tobacco plus various vegetable
    materials) produce high levels of tar and nicotine (Simarak et al.,
    1977).

    For smoking, tobacco leaf can be flue-cured, light air-cured,
    fire-cured or sun-cured, and can be of dark, oriental or  N. rustica
    type. Flue-cured tobacco is used for cigarettes and pipe tobacco.
    Air-cured tobacco is used in blended cigarettes. Dark tobaccos are
    widely grown, usually air-cured, and mostly used in their countries of
    origin for dark cigarettes, "bidis", cigars, in pipes and "sheeshas",
    and for chewing tobaccos and snuff (Voges, 1984). Some tobaccos have
    low nitrate levels ranging up to 0.9% (Neurath & Ehmke, 1964; Wynder &
    Hoffmann, 1967) and their smoke contains low nitrogen oxide levels in
    the range of 50-200 mg NOx/cigarette (Norman et al., 1983). In the
    reducing atmosphere of the burning cone, NOx gives rise to amino
    radicals, which react with benzene, biphenyl, naphthalene and other
    ring hydrocarbons to form aromatic amines. Aniline, alkylated
    anilines, aminobiphenyls, and naphthylamines are therefore found in
    higher quantities in the smoke of tobaccos with a high nitrate content
    (Patrianakos & Hoffmann, 1979; Pieraccini et al., 1992; Grimmer et
    al., 1995). Smokers of these tobaccos can inhale greater quantities of
    aromatic amines, such as the human bladder carcinogens
    2-naphthyl-amine and 4-aminobiphenyl, and have higher concentrations
    of haemoglobin adducts in their blood (Bartsch et al., 1993). This is
    the basis for the higher risk of bladder cancer among the smokers of
    cigarettes made from dark tobaccos (Vineis et al., 1984; D'Avanzo et
    al., 1990; Vineis, 1992).

    In the Indian subcontinent, the "bidi" is the common smoking device.
    It consists of tobacco flakes, loosely packed and hand-rolled in a
    tendu or temburni leaf ( Diospyros melanoxylon). It contains less
    tobacco (0.223 g) than a cigarette (0.782 g) (Ramakrishnan et al.,
    1995) but up to 8.2% nicotine compared with up to 3.7% in cigarette
    tobacco. "Bidi" smoke contains 23 to 48 mg tar and 1.7 to 2.9 mg
    nicotine per cigarette (Hoffmann et al., 1974; Jayant & Pakhale,
    1985). In India, where around 7% of world tobacco is consumed (US DA,
    1990), around 30% of tobacco is smoked as cigarettes, 50% as "bidis",
    10% in other ways, and 10% is used for chewing. "Bidis" need to be
    puffed frequently to ensure even burning and can generate up to 70 mg
    of carbon monoxide, while a US non-filter cigarette smoked under
    identical conditions generated 25 mg carbon monoxide (Hoffmann et al.,
    1974; Jayant & Pakhale, 1985).


        Table 2. Estimated smoking prevalence, ranked in order of male smoking prevalencea

                                                                                                                                 

    Rank Countryb                      Men            Women             Rank   Country                     Men            Women
                                       (%)            (%)                                                  (%)            (%)
                                                                                                                                 

    1    Republic of Korea (1989)      68.2           6.7               21     Seychelles (1989)           50.9           10.3
    2    Latvia (1993)                 67             12                22     Bolivia (1992)              50             21.4
    2    Russian Federation (1993)     67             30                23     Albania (1990)              49.8           7.9
    4    Dominican Republic (1990)     66.3           13.6              24     Cuba (1990)                 49.3           24.5
    5    Tonga (1991)                  65             14                25     Bulgaria (1989)             49             17
    6    Turkey (1988)                 63             24                25     Thailand (1995)             49             4
    7    China (1984)c                 61             7                 27     Spain (1993)                48             25
    8    Bangladesh (1990)             60             15                28     Mauritius (1992)            47.2           3.7
    9    Fiji (1988)                   59.3           30.6              29     Greece (1994)               46             28
    10   Japan (1994)                  59             14.8              29     Papua New Guinea (1990)     46             28
    11   Sri Lanka (1988)              54.8           0.8               31     Israel (1989)               45             30
    12   Algeria (1980)                53             10                32     Cook Islands (1988)         44             26
    12   Indonesia (1986)              53             4                 33     Czech Republic (1994)       43             31
    12   Samoa (1994)                  53             18.6              33     Jamaica (1990)              43             13
    15   Saudi Arabia (1990)           52.7           N/Ad              33     Philippines (1987)          43             8
    16   Estonia (1994)                52             24                33     Slovakia (1992)             43             26
    16   Kuwait (1991)                 52             12                37     Cyprus (1990)               42.5           7.2
    16   Lithuania (1992)              52             10                38     Austria (1992)              42             27
    16   South Africa (1995)           52             17                39     Malaysia (1986)             41             4
    20   Poland (1993)                 51             29                39     Peru (1989)                 41             13
    41   Uruguay (1990)                40.9           26.6              66     Colombia (1992)             35.1           19.1
    42   Argentina (1992)              40             23                67     Costa Rica (1988)           35             20
    42   France (1993)                 40             27                67     Slovenia (1994)             35             23
    42   Hungary                       40             27                69     Swaziland (1989)            33             8
    42   India (1980s)                 40             3                 70     Luxembourg (1993)           32             26
    42   Iraq (1990)                   40             5                 71     Singapore (1995)            31.9           2.7
    42   Malta (1992)                  40             18                72     Belgium (1993)              31             19
    50   Brazil (1989)                 39.9           25.4              72     Canada (1991)               31             29
    51   Egypt (1986)                  39.8           1                 72     Iceland (1994)              31             28
    52   Morocco (1990)                39.6           9.1               75     Australia (1993)            29             21
    53   Lesotho (1989)                38.3           1                 75     Ireland (1993)              29             28
    53   Mexico (1990)                 38.3           14.4              77     UK (1994)                   28             26
    55   El Salvador (1988)            38             12                78     USA (1993)                  27.7           22.5

    Table 2. (cont'd)

                                                                                                                                 

    Rank Countryb                      Men            Women             Rank   Country                     Men            Women
                                       (%)            (%)                                                  (%)            (%)
                                                                                                                                 

    55   Italy (1994)                  38             26                79     Pakistan (1980)             27.4           4.4
    55   Portugal (1994)               38             15                80     Finland (1994)              27             19
    58   Chile (1990)                  37.9           25.1              81     Turkmenistan (1992)         26.6           0.5
    59   Guatemala (1989)              37.8           17.7              82     Nigeria (1990)              24.4           6.7
    60   Denmark (1993)                37             37                83     Paraguay (1990)             24.1           5.5
    61   Germany (1992)                36.8           21.5              84     Bahrain (1991)              24             6
    62   Norway (1994)                 36.4           35.5              84     New Zealand (1992)          24             22
    63   Honduras (1988)               36             11                86     Sweden (1994)               22             24
    63   Netherlands (1994)            36             29                87     Bahamas (1989)              19.3           3.8
    63   Switzerland (1992)            36             26
                                                                                                                                 

    a  Adapted from: WHO (1997).
    b  The year given in parentheses is the latest available year for data.
    c  Some 1991 data suggest that there has been little change in smoking prevalence since 1984.
    d  Data not available.

    Table 3.  Trends in adult consumption of cigarettes from 1970-1972 to 1990-1992 (Adapted from WHO, 1997)

                                                                                                                

                                                      Annual % change
                                                      1970-1972 to 1990-1992
                                                                                                                
    WHO Regions:
         African Region                               +1.2
         Region of the Americas                       -1.5
         Eastern Mediterranean Region                 +1.4
         European Region                              0
         South-East Asia Region                       +1.8
         Western Pacific Region                       +3
    More developed countries                          -0.5
    Less developed countries                          +2.5
    World                                             -0.8
                                                                                                                
    

    Tar yields for Russian cigarettes were found to be high (21.6-29.2
    mg) and cigarettes containing  N. rustica produced high smoke
    concentrations of tobacco-specific nitrosamines (TSNA) (up to 620 ng
    total TSNA/cigarette) (Djordjevic et al., 1991). Indigenous cigarettes
    and cigars in Thailand, containing tobacco and other vegetable
    materials, have up to 41 mg and 200 mg tar, up to 5.5 mg and 11.4 mg
    nicotine, and 41 mg and 820 mg carbon monoxide in cigarette and cigar
    smoke, respectively. Indonesian cigarette smoke contains up to 100 ng
    of carcinogenic volatile  N-nitrosamines and up to 1580 ng of
    carcinogenic tobacco-specific  N-nitrosamines (Mitacek et al., 1990,
    1991), and high tar cigarettes contain up to 28.1 mg tobacco-specific
     N-nitrosamines per cigarette (Brunnemann et al., 1996).

    Many cigar-like devices are smoked throughout Asia. The tobacco can be
    rolled in a tobacco leaf or in the leaves of the jackfruit tree
    ( Artocarpus integrifolia), banana ( Musa paradisiaca) or hansali
    ( Grewia microcos) (Bhonsle et al., 1976). They may be smoked
    conventionally or in the reverse manner with the burning end inside
    the mouth (Reddy, 1974). In Thailand they can contain strong tobacco
    and a mixture of koi bark ( Streblus asper), dry tamarind pod
    ( Tamarindus indica), khai bark ( Homonoia riparia, Euphorbiaceae),
    Areca palm bark ( Areca catechu) or other tree bark; they can be
    rolled in a banana leaf or have fragrant additives such as sandalwood
    Mougne et al. (1982). They contain high levels of tar and nicotine
    (Simarak et al., 1977; Mitacek et al., 1999).

    Additives are used to enhance the fragrance or taste of smoke
    (Hoffmann & Hoffmann, 1997). "Casing sauces", consisting of sugars,
    aromatic substances and compounds such as glycerol, propylene glycol,
    ethylene glycol and diethylene glycol, which resist changes in
    moisture content, are sprayed on the leaf before it is cut to
    condition it for processing. Flavouring and dressing compounds are
    added to cut tobacco after drying and include licorice, menthol,
    cocoa, chocolate, ginger, cinnamon, vanilla, molasses, angelica,
    honey, essential oils from anise, clove and juniper, resins and plant
    extracts and organic compounds such as coumarins. Additives have been
    widely used in pipe and chewing tobaccos. They have also become
    important in cigarette tobacco with the development of low-tar and
    low-nicotine tobaccos and the use of stem, midrib or reconstituted
    leaf (which lacks the aromas and flavours of natural tobacco leaf
    lamina) and of tobacco dust requiring additives to ensure its
    adherence to cut tobacco.

    Added glycerol is transferred to mainstream smoke: 3-6% in cigarette
    smoke and 35-43% in pipe smoke (IARC, 1986) and one of its pyrolysis
    products is acrolein. Levels of acrolein ranging from 69 mg to 230 mg
    per cigarette have been reported and air concentrations as high as
    0.46 mg/m3 have been found in smoke-filled rooms (Izard & Liberman,
    1978). Acrolein is extremely irritating to the eyes and nasal mucosa,
    it affects mitotic and ciliary activity, at the cellular level it has
    cytotoxic and cilia-depressant effects, and it can act as a mutagen
    (Izard & Liberman, 1978).

    In the USA, additives used in cigarette manufacture are food additive
    compounds that are "generally recognized as safe (GRAS)" and,
    therefore, also considered "safe" as additives to tobacco. However,
    the non-volatile additives are to some extent pyrolized during smoking
    and can give rise to toxic and/or carcinogenic agents in the smoke. A
    major group of compounds formed during pyrolysis is that of the
    polynuclear aromatic hydrocarbons. Ethylene glycol is pyrolytically
    converted to the human carcinogen ethylene oxide (IARC, 1994a).

    Another example of carcinogen formation during tobacco curing and
    smoking is the case of MH-30, a sucker growth control agent formulated
    from maleic hydrazide in diethanolamine. Residual MH-30 on tobacco
    leads to the formation of  N-nitrosodiethanolamine (NDELA) in the
    smoke (Brunnemann & Hoffmann, 1981). The use of MH-30 on tobacco has
    been forbidden in the USA since 1981, and NDELA levels in tobacco and
    its smoke have declined (Brunnemann & Hoffmann, 1991).

    The use of cloves as a tobacco additive can have health effects. In
    Indonesia, the smoke of "kreteks", a blend of ground cloves with 
    60-65% of tobacco, contains between 41 and 113 mg of tar, and between 
    1.2 and 4.5 mg nicotine (WHO, 1985; Wise & Guerin, 1986). Mainstream 
    smoke of kreteks without filter tips contains 19-23 mg of eugenol 
    released from the cloves, while filter-tipped kretek smoke contains up
    to 15 mg (LGC, 1982; Wise & Guerin, 1986). Inhalation of eugenol in 
    the smoke of kreteks can lead to interstitial haemorrhaging and 
    congestion of the lung, acute emphysema and acute pulmonary oedema. 
    These effects were also seen in Syrian golden hamsters exposed to the
    smoke of kreteks (LaVoie et al., 1986).

    Menthol and other additives that produce a sensation of coolness but
    without a mint flavour have also been used in cigarettes. There is no
    evidence that these additives result in a higher risk (Cummings et
    al., 1987; Sidney et al., 1989).

    Many shapes and sizes of smoking pipes are found worldwide (Voges,
    1984). Various types of tobacco are used and the smoke can range from
    mild to very strong. In the sheesha water pipe the tobacco is kept
    alight by pieces of glowing charcoal and the smoke is drawn through
    water before being inhaled. Sheesha smoke is mild and low in
    particulate matter, benzo( a) pyrene and volatile phenols (Hoffmann
    et al., 1961), but it has a high level of carbon monoxide, in part
    from the charcoal that keeps the tobacco burning, and smokers have
    high carboxyhaemoglobin levels and a reduced FEV1 (8.5% in women, 45%
    in men) (Zahran et al., 1985; Al-Fayez et al., 1988).

    2.1.3  Tobacco chewing and snuff

    The popularity of tobacco chewing and snuff (finely powdered tobacco
    leaf) has varied. Nasal inhalation of snuff has given way to the oral
    application of snuff and other tobacco-containing mixtures between the
    gum and lip, or gum and cheeks, or under the tongue. Chewing tobacco
    comes in several forms and may have flavour added from syrups,
    liquorice and brandy. Tobacco chewing has retained its popularity in

    heavy industries, such as steel and coal mining, woodworking and the
    petroleum industry, where the flammability hazard precludes smoking.
    In Sweden, 17% of the population uses oral snuff. In the USA, sales of
    chewing tobacco have declined but sales of oral snuff have increased
    by 61% (US DA, 1997) owing to the popularity of the latter with
    teenagers and young adult men. Oral tobacco use in India is very
    common but, generally, in developing countries it is declining because
    urban populations and younger age groups are smoking cigarettes.

    "Betel-quid" chewing is common in Asia and Africa. The basic contents
    of a betel-quid are slices of areca nut ( Areca catechu), lime and
    tobacco, wrapped in a betel pepper leaf ( Piper betle), but it may
    also contain dried dates, menthol and spices such as cardamom, cloves,
    coriander, mace and cinnamon.

    Other tobacco preparations for oral use often contain lime, calcium
    carbonate, sodium carbonate, some form of ash or flavouring materials.
    The lime and other agents assist the release of nicotine (Voges, 1984;
    Idris et al., 1991).

    2.2  Responses to mainstream smoke

    Tobacco use has direct effects on health and is responsible for a
    variety of diseases. These form a basis for studying interactions
    between tobacco use and chemical, physical and biological agents, and
    associated effects on health.

    2.2.1  Acute responses

    Inhaled irritant chemicals cause inflammation of the upper respiratory
    tract (URT) and paranasal sinuses, sore throat and bronchial oedema.
    Pulmonary oedema may follow if irritants penetrate the lower
    respiratory tract. Acute irritation of the URT usually follows
    inhalation of highly soluble gases. Slightly less soluble gases cause
    URT and bronchial irritation, while relatively insoluble gases
    penetrate deeply into the lung and can have delayed effects including
    pulmonary oedema (Miller & Kimbell, 1995). Cigarette smoke is a
    complex mixture of organic and inorganic constituents with particulate
    and vapour phases and highly reactive free radicals (Hocking & Golde,
    1979). It contains many compounds with irritant properties, which can
    affect all parts of the lung. Kremer et al. (1994) examined the
    association between occupational exposures to a variety of airway
    irritants and respiratory system effects, and whether the association
    was modified by smoking, airway hyperresponsiveness and allergy. The
    irritants were SO2, HCl, SO42-, polyester vapour, polyamide vapour,
    and oil mist and vapour. Current smoking, airway hyperresponsiveness
    and allergy were significantly associated with a higher prevalence of
    chronic respiratory symptoms, independent of each other and of
    irritant exposure. The association between exposure and the prevalence
    of chronic respiratory symptoms was greater in smokers than in non- or
    ex-smokers.

    2.2.1.1  Acute bronchitis

    Acute bronchitis is an inflammation of the bronchial mucous membrane,
    initially accompanied by a dry painful cough and followed by
    mucopurulent sputum. The cause may be infectious agents or chemical
    agents such as tobacco smoke, dusts, fumes, vapours or gases.

    2.2.1.2  Asthma

    Asthma is a chronic pulmonary inflammatory disease associated with
    bronchial hyperreactivity causing paroxysmal dyspnoea due to spasm of
    the bronchial musculature, swelling of the mucous membranes and the
    production of viscid mucus. In the majority of asthma cases a clear
    association exists with atopic IgE-mediated hypersensitivity. Allergic
    asthma is a response to a specific agent. Many chemical agents,
    including mixtures such as tobacco smoke, can induce asthma. Smoking
    enhances the effect of other agents and can reduce the latent period
    from first exposure to onset of sensitization.

    There has been an increase in the prevalence of asthma in many
    countries, and roles for environmental factors, increased
    susceptibility and tobacco smoking have been suggested (ISAAC, 1998).
    Cigarette smoking together, with atopic status, age, URT infection and
    genetic factors, has been considered to increase susceptibility
    (Venables et al., 1985; Seaton et al., 1993). Studies have shown a
    relationship between cigarette smoking and serum IgE levels. Smokers
    have higher levels of IgE with increasing age, compared to non-smoking
    controls. A relationship has also been observed between IgE level and
    the number of cigarettes smoked (Sherrill et al., 1994).

    2.2.2  Chronic responses

    2.2.2.1  Chronic obstructive lung diseases

    The chronic obstructive lung diseases (COLD) are chronic bronchitis,
    small airways disease, toxic bronchiolitis obliterans, emphysema and
    fibrosis (Niewoehner et al., 1974; Niewoehner, 1991).

    These diseases form an important group of pulmonary diseases caused by
    smoking (and by chemical atmospheric pollution) (US Surgeon General,
    1984). In a study by Simecek et al. (1986) of 215 229 adults in a
    region of former-Czechoslovakia, smoking was the most important risk
    factor in COLD. Risks for male non-smokers and light smokers under 30
    years of age were 1.18% and 2.28%, respectively; for men aged 50
    years, smoking more than 20 cigarettes a day, the risk was 20.36%
    compared with 3.31% for non-smokers of the same age. In the USA, 
    80-90% of the mortality from COLD has been attributed to cigarette
    smoking. Cigar and pipe smokers who inhale the smoke also have an
    increased death rate from COLD (US Surgeon General, 1984, 1989; NIH,
    1998). Between 1979 and 1993, the age-adjusted annual death rate from

    COLD in women increased by 122% to 17.1 per 100 000, while in men it
    increased by 14% to 27.8 per 100 000. The greater increase of COLD
    among women during this period reflected the increase in smoking by
    women.

    2.2.2.2  Chronic bronchitis

    Chronic bronchitis has been variously defined. The United Kingdom
    Medical Research Council (MRC, 1965) considered it to be a condition
    with persistent production of sputum, which might be associated with
    cough, occurring on most days for at least three months in the year
    for at least two successive years. The Council recommended a
    classification of simple chronic bronchitis, chronic or recurrent
    mucopurulent bronchitis or chronic obstructive bronchitis. In a
    workplace context, Morgan (1982) defined it as "a condition
    characterized by cough and sputum for at least three months of the
    year, which may or may not be accompanied by airways obstruction, and
    which is a consequence of prolonged inhalation of dust or irritant
    gases at the workplace". Fletcher & Pride (1984) suggested an improved
    terminology with the term chronic bronchitis meaning chronic or
    recurrent bronchial hypersecretion only, abandoning the term chronic
    obstructive bronchitis because this implies a causal connection
    between mucus hypersecretion and airflow obstruction. In smokers'
    lungs the irritant constituents of tobacco smoke cause hypersecretion
    of mucus, alter its physical properties and chemical structure, and
    impair the mucociliary clearance mechanism. Removal of major
    ciliatoxins (hydrogen cyanide and volatile aldehydes) from the smoke
    stream by charcoal filter tips reduces the effects on the lung
    epithelium (Friedman et al., 1972). Mineral dusts, particularly those
    encountered in mining, many biological dusts, irritant vapours and
    gases, inorganic and organic chemical dusts and sprays can all cause
    chronic bronchitis.

    2.2.2.3  Small airways disease

    Small airways disease (SAD) is a widespread narrowing of membranous
    bronchioli. It is inflammatory in origin and is often associated with
    excess mucus and an accumulation of macrophages in the respiratory
    bronchioli. SAD is mainly caused by smoking, but can be associated
    with environmental and industrial pollutants (Cosio et al., 1980).

    2.2.2.4  Emphysema

    Emphysema has been defined as a condition of the lung characterized by
    an abnormal enlargement of the airspaces distal to the terminal
    non-respiratory bronchioli, accompanied by destructive changes in the
    alveolar walls, and without obvious fibrosis. It tends to be prevalent
    in older age groups and follows SAD. For purposes of postmortem
    examination of lung slices of miners, Ruckley et al. (1984) defined
    emphysema as the presence of air spaces of 1 mm or more in size.
    Macrophages that have engulfed foreign particles, including smoke
    particulate matter in the lungs of smokers, and which have been found
    accumulated in the bronchioli (Niewoehner et al., 1974) and in the

    lung parenchyma (McLaughlin & Tueller, 1971) have been implicated in
    the pathogenesis of emphysema. There are different forms of emphysema,
    which vary with the nature of the insult to the tissues. One
    hypothesis is that tobacco smoke causes increased production and
    release of proteolytic enzymes, such as elastase, and interferes with
    normal antiproteolytic mechanisms. Emphysema has been induced
    experimentally in animals by endotracheal installation of elastase or
    homogenates of alveolar macrophages or polymorphonuclear leukocytes.
    Chronic exposure to tobacco smoke has a number of effects on alveolar
    macrophages, including changes in metabolism, alteration of the enzyme
    content and impairment of RNA and protein synthesis (Hocking & Golde,
    1979). The function of alveolar macrophages is to remove inhaled
    foreign material from the alveoli and respiratory bronchioles, and
    their numbers increase when the lungs are exposed to particles and
    gases. It has been demonstrated that the macrophage count is higher in
    people exposed to cigarette smoke than in non-exposed people (Harris
    et al., 1974; Rylander et al., 1979). Alveolar macrophages from
    smokers are more active than those from non-smokers, numbers are
    increased, there are morphological changes with an increased cell
    diameter, crystalline inclusions and surface membrane alteration
    (Sopori et al., 1994).

    2.2.2.5  Pulmonary fibrosis

    Pulmonary fibrosis is the abnormal formation of fibrous or scar tissue
    and is the response of bronchiolar tissue to the deposition of an
    inhaled inciting agent. Mineral and other dusts are causes of
    pulmonary fibrosis. The radiological changes seen in early stages of
    dust fibroses are associated with relatively minor lung function
    impairment, but continuous exposure leads to a greater degree of
    fibrosis and to progressive massive fibrosis in some subjects. On
    histological, animal experimental and radiographic evidence, Weiss
    (1984) concluded that cigarette smoking could cause diffuse fibrosis.

    2.2.2.6  Effects on the immune system

    Tobacco smoking and exposure to environmental tobacco smoke increase
    susceptibility to pulmonary infections, and changes in immune
    processes may be involved. Tobacco smoking affects humoral and
    cellular immunity in humans and experimental animals, but the
    magnitude of the changes vary widely among studies. In humans,
    cigarette smoke has marked effects on alveolar macrophage morphology
    and physiology, it decreases serum immunoglobulin (IgA, IgG, IgM) but
    increases IgE, and has a range of effects on B- and T-lymphocytes.
    Similar effects are found in experimental animals (Sopori et al.,
    1994). Studies in rats and mice show that cigarette smoke or nicotine
    induces impaired responses of systemically distributed B- and
    T-lymphocytes to antigen-induced signalling (Geng et al., 1995, 1996).
    T-lymphocyte unresponsiveness, with decreased antibody response to
    T-dependent antigens, is important in response to infection (Sopori et
    al., 1998).

    2.2.3  Cancer

    Many forms of cancer have been associated with inhaled particulate
    matter, vapours, fumes and gases. Examples are lung cancer associated
    with tobacco smoking and inhalation of asbestos, fumes from metal
    moulding and coking plants, particles and gases inhaled by motor
    vehicle drivers, dusts in several types of mines where there is an
    accumulation of alpha-emitting radioisotopes, and contact with
    materials such as arsenic, chromates, nickel, chloromethyl ethers,
    mustard gas and polycyclic aromatic hydrocarbons. Pleural mesothelioma
    has been associated with asbestos, nasal and sinus cancer with nickel
    refining and wood dust exposure, leukaemia with ionizing radiations
    and benzene, bladder cancer with the manufacture and use of dyes and
    in the rubber industry, and liver cancer with the use of vinyl
    chloride (IARC, 1987).

    Cigarette smoke contains many toxic chemicals, including chemicals
    that are DNA reactive and cytotoxic or become DNA reactive upon
    metabolic activation. Consequently, cigarette smoke has the potential
    to initiate genetic lesions. Moolgavkar et al. (1989) postulated
    mechanisms by which cigarette smoke induces lung cancer by fitting the
    two-stage clonal expansion model of carcinogenesis to lung cancer
    mortality data derived from a large cohort of British doctors who
    smoked. This analysis suggested that tobacco smoke affected both the
    rates of mutation and cell proliferation involved in the model,
    supporting the hypothesis that tobacco smoke acts as a complete
    carcinogen.

    Cigarette smoking is causally associated with cancer of the lung,
    larynx, pharynx, oesophagus, pancreas, kidney and urinary bladder. It
    is also associated with cancer of the nasal cavity, liver, uterine
    cervix and myeloid leukaemia (RCP, 1962; US Surgeon General, 1982,
    1989; IARC, 1986; Winkelstein, 1990; Brownson et al., 1993; Roush,
    1996).

    In 1991, in the USA, it was estimated that 90.3% of the lung cancer
    deaths in men and 78.5% of lung cancer deaths in women were
    attributable to cigarette smoking. Deaths from oesophageal cancer were
    linked to smoking in 78.2% of the cases in men and 74.3% of the cases
    in women. Smoking was held responsible for 81.2% of deaths from
    laryngeal cancer in men and 86.7% in women, for 91.5% and 61.2%,
    respectively, of deaths from oral cancer, and 46.5% and 36.7%,
    respectively, of deaths from bladder cancer. Smoking-attributable
    deaths from cancer of the kidney in men and women were 47.6 and 12.3%,
    respectively, and for pancreatic cancer the figures were 28.6% and
    33.3% respectively. In women, 32.4% of uterine cervical cancer deaths
    were attributed to cigarette smoking (Shopland et al., 1991).

    There has been a change in the rates of different types of lung cancer
    among smokers. In 1950, squamous cell carcinoma (SCC) occurred 17
    times more often than adenocarcinoma (AC) (Wynder & Graham, 1950) in
    cigarette smokers. In 1991, Devesa et al. (1991) reported that in male
    cigarette smokers the ratio of SCC to AC was 2.4:1 between 1969 and

    1971, and changed to 1.4:1 between 1984 and 1986; in cigarette-smoking
    women, the SCC to AC ratio changed from 3.6:1 in 1950 to 0.57:1 in
    1984-1986. Between 1970 and 1980 some studies showed a 20-50%
    reduction in risk of lung cancer for long-term smokers of filter
    cigarettes as compared to smokers of non-filter cigarettes (IARC,
    1986) but later studies indicated a similar risk for lung cancer in
    smokers of filter and non-filter cigarettes (Stellman et al., 1997;
    Thun et al., 1997). The changes in the ratio of SCC to AC, and the
    disappearance of an advantage of filter cigarette smoking in terms of
    lung cancer risk, have been related to changes in smoke yields, which
    have caused smokers to modify patterns of puff drawing and smoke
    inhalation. Smokers regulate the speed and the quantity of their
    nicotine uptake to achieve the desired pharmacological effects
    (Benowitz et al., 1988; Djordjevic et al., 1995). Smokers of lower
    nicotine cigarettes draw puffs of greater volume, at a higher
    frequency, and inhale more deeply; this is governed by the amount of
    nicotine in the smoke (Wynder & Hoffmann, 1994).

    Smoking is a major risk factor for the early stage development of
    oesophageal and gastric adenocarcinomas, accounting for 40% of cases,
    and may have contributed to the increase in the incidence of these
    cancers, especially in older people (Gammon et al., 1997).

    Cigar smoking is causally associated with cancer of the oral cavity,
    the pharynx and the lung, even though for cigar smokers, who do not or
    only minimally inhale the smoke, the lung cancer risk is considerably
    lower than that for cigarette smokers. Cigar smoking is also
    associated with cancer of the pancreas and of the urinary bladder
    (NIH, 1998). Oral snuff users have an increased risk of cancer of the
    oral cavity and, possibly, cancer of the oesophagus, pancreas and
    urinary bladder (US Surgeon General, 1986).

    It has been suggested that around 4-5% of all lung cancer is related
    to occupational exposure (Wynder & Gori, 1977; Doll & Peto, 1981;
    Morgan, 1982 ). Occupational and any other forms of exposure to
    chemical compounds are of limited importance in the etiology of lung
    cancer whereas tobacco smoking is the cause of approximately 85-90% of
    cases (Shopland et al., 1991).

    "Reverse smoking", in which rolled tobacco leaves are smoked with the
    burning end inside the mouth, has been linked to carcinoma of the hard
    palate (Reddy & Rao, 1957; Mehta et al., 1971; Pindborg et al., 1971;
    Reddy, 1974; Bhonsle et al., 1976). Reddy et al. (1960) simulated the
    effect of reverse smoking experimentally by painting the skin of male
    and female mice on alternate days with the tar from Indian cigars and
    exposing the painted skin to a temperature of 58°C for 3 min; the heat
    treatment enhanced the dermal tumour response.

    2.2.4  Cardiovascular effects

    Cigarette smoking is a major independent risk factor for
    cardiovascular disease (CVD). Cigarette smoking acts synergistically
    with other risk factors, such as elevated cholesterol levels and

    hypertension (Wilhelmsen, 1977; Gibinski, 1977; US Surgeon General,
    1983). Prospective studies indicated that elevated cholesterol and
    hypertension appear to be prerequisites for CVD in cigarette smokers
    (Kimura, 1977). It has been estimated that in countries with a long
    history of cigarette smoking the tobacco habit is responsible for 
    26-30% of early deaths from CVD (US Surgeon General, 1983; Wald et 
    al., 1985). Those who smoke several cigars a day and inhale the smoke 
    also face an increased risk of CVD (NIH, 1998).

    The major contributors to the cardiovascular effects of tobacco smoke
    are carbon monoxide and nicotine (Lakier, 1992), as well as nitrogen
    oxides (NOx), hydrogen cyanide and tar; minor contributors are
    cadmium, zinc and carbon disulfide (US Surgeon General, 1983). The
    smoke of cigarettes can be slightly acidic (pH 5.6-5.9) or weakly
    alkaline (pH 6.7-7.9) depending on the type of tobacco and the blend
    (Brunnemann & Hoffmann, 1974). In the slightly acidic smoke, nicotine
    is protonated, i.e., bound to a salt or acid moiety and is part of the
    particulate phase. Weakly alkaline smoke contains a small percentage
    of protonated nicotine (often up to 50% of the nicotine is
    unprotonated) in the vapour phase. In contrast to the protonated
    variety, unprotonated nicotine is rapidly absorbed through the oral
    mucosa and this is why smokers of cigarettes with weakly acidic smoke
    and smokers of cigars do not need to inhale into the lung to
    experience the pharmacological effects of nicotine. Protonated
    nicotine in the particulate matter of slightly acidic cigarette smoke
    is not or is only minimally absorbed through the oral mucosa, so that
    smokers inhale the smoke and absorption into the bloodstream takes
    place in the lung (Armitage & Turner, 1970; Russell, 1976; Benowitz et
    al., 1988).

    Smoking has been associated with a two-to-fourfold increased risk of
    coronary heart disease (CHD), a greater than 70% excess rate of death
    from CHD, and an elevated risk of sudden death (Lakier, 1992).
    Nicotine causes increases in heart rate and blood pressure, stimulates
    nerve endings that are activated by acetylcholine, causes increased
    mobilization of free fatty acids in the serum and enhances platelet
    adhesiveness. These effects increase cardiac load (which for
    individuals with some forms of heart disease will not be met by
    increased coronary blood flow) and interfere with metabolic exchange
    across capillary walls, leading to ischaemic episodes and thrombosis.
    Carbon monoxide increases carboxyhaemoglobin concentrations in the
    blood and lowers its oxygen-carrying capacity: increased oxygen debt
    after exercise and impairment of endurance performance are evident in
    smokers, compared to non-smokers. Carbon monoxide also has an affinity
    for myoglobin and interferes with oxygen uptake by the myocardium.

    "Bidi" smoke contains a higher concentration of carbon monoxide than
    cigarette smoke (Hoffmann et al., 1974; Jayant & Pakhale, 1985; Ball &
    Simpson, 1987). Most of the Asian smoking devices with their
    non-porous wrappers and dark tobacco contain higher levels of nicotine
    (Simarak et al., 1977; WHO, 1985). High nicotine and carbon monoxide
    are also obtained from many dark tobacco cigarettes and from cigars.
    "Sheesha" water pipe smoke contains small amounts of nicotine but is

    rich in carbon monoxide; the blood carboxyhaemoglobin concentration in
    sheesha smokers is higher than in cigarette smokers (Zahran et al.,
    1985).

    Cigarette smoking has been considered to be the primary cause of
    Buerger's disease (thromboangiitis obliterans), an inflammatory
    obliterative, non-atherosclerotic, vascular disease. The disease
    usually becomes quiescent if the patient stops smoking cigarettes
    (Olin, 1994). It was rare in women but an increasing number of cases
    has been observed and ascribed to the increased use of tobacco by
    young women (Yorukoglu et al., 1993).

    Cardiovascular disease has been associated with exposure to other
    factors, which can be classified as physical, chemical and biological,
    and with occupation or life-style. The combination of smoking with any
    of these factors will predispose to an increased detrimental
    cardiovascular effect.

    In women who smoke, peripheral vasoconstriction (PV) leading to acute
    intervillous placental blood flow was measured during smoking and
    attributed to nicotine, which simultaneously caused increases in heart
    rate and blood pressure. It was suggested that PV explained fetal
    growth retardation and other complications of pregnancy (Lehtovirta &
    Forss, 1978).

    2.2.5  Smoking and occupational accidents, injuries and
           absenteeism

    A survey of public employees found that cigarette smokers took 23%
    more sick leave than non-smokers (Van Tuinen & Land, 1986). In another
    study among 2537 postal workers in the USA, cigarette smokers had a
    1.29 times higher accident rate (CI 1.07-1.55), and a 1.55 times
    higher injury rate (CI 1.11-1.77) than non-smokers (Ryan et al.,
    1992). Other studies confirm the higher rates of injury, occupational
    accidents and absenteeism in smokers (Naus et al., 1966; Parka, 1983;
    US Surgeon General, 1985; Hawker & Holtby, 1988). There are higher
    costs of illness for cigarette smoking employees compared to
    non-smokers (Van Peenen et al., 1986; Penner & Penner, 1990.

    2.3  Health risks from smokeless tobacco use

    2.3.1  Introduction

    Oral cancers have been linked with oral tobacco use. The consequences
    of chewing tobacco can be reactional keratosis, irreversible gingival
    recession, periodontitis, oral dysplasia and leukoplakia, cancer and
    cardiovascular effects (Chakrabarti et al., 1991; Guggenheimer, 1991).
    In India, chewing material containing tobacco has been shown to be a
    primary cause of oral cancer (Jussawalla & Deshpande, 1971).

    2.3.2  Cancer

    Leukoplakia and oral cancer are common results of oral tobacco use,
    particularly in the countries of Asia (IARC, 1985a). Simarak et al.
    (1977) reported a strong association between betel chewing and oral
    cancer in northern Thailand. Sankaranarayanan et al. (1989a,b, 1990)
    associated oral cancers in southern India with tobacco chewing.
    Chakrabarti et al. (1991) reported much higher levels of pre-malignant
    and malignant lesions of the oral cavity in tobacco chewers;
    Nandakumar et al. (1990) found the relative risk to be elevated in
    both sexes, but appreciably higher in females. From chemical analysis
    of Indian tobacco products, it was concluded that their use may lead
    to high exposures to carcinogenic tobacco nitrosamines (Nair et al.,
    1989).

    Case-control studies reported a higher incidence of oral cancer in
    oral snuff users than in those not using any form of tobacco. There
    was up to a 50-fold excess risk of cancer of the cheek and gum in
    long-term oral snuff users (Axéll et al., 1978; US Surgeon General,
    1986a; Winn, 1997). Idris et al. (1991, 1994), reported a high
    incidence rate of oral cancer in men in northern Sudan who used an
    oral snuff with relatively high concentrations of nicotine (0.8-3.2%)
    and nornicotine. In a study of baseball players who chewed or (the
    majority) used snuff orally, there was higher prevalence of
    leukoplakia, plaque formation, gingivitis and dental disorders
    compared to non-users (Robertson et al., 1997).

    A case-control study on nasal cavity and paranasal sinus cancer and
    snuff use showed that snuff users have a significantly increased risk
    for adenocarcinoma and squamous cell carcinoma in the nasal cavity
    (Brinton et al., 1984).  N'-nitrosonornicotine is present and is an
    organ-specific carcinogen that induces benign and malignant tumours of
    the nasal cavity in rats, hamsters and mink (Rivenson et al., 1991;
    Koppang et al., 1992, 1997; Hoffmann et al., 1994). Studies conducted
    in South Africa showed that people using local snuff made from tobacco
    and aloe plant ash as nasal applications have an increased risk for
    tumours of the maxillary antrum (Keen et al., 1955). It was thought
    that this snuff mixture contained high levels of nickel and chromium,
    which may be associated with the induction of these tumours (Baumslag
    et al., 1971).

    Instillation of snuff into the lips of rats induced benign and
    malignant tumours in the oral cavity (Hirsch & Thilander, 1981; Hecht
    et al., 1986; Johansson et al., 1989; Larsson et al., 1989).
    Instillation of snuff into the buccal pouch of hamsters, which were
    repeatedly infected with  Herpes simplex virus type I or II, led to
    oral tumours, although no tumours occurred when either the virus or
    tobacco was applied alone (Park et al., 1991b).

    More than 3050 chemical compounds have been identified as tobacco
    constituents (Roberts, 1988) and 50 are known carcinogens (Brunnemann
    & Hoffmann, 1992). Nitrosamines, especially the tobacco-specific
    nitrosamines (TSNA), must be regarded as major oral carcinogens. Oral

    tumours were elicited when an aqueous solution of N-nitrosonornicotine
    (NNN) and 4(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) was
    applied to the oral surfaces of rats (Hecht et al., 1993).

    2.3.3  Cardiovascular disease

    The effect of tobacco chewing on cardiovascular disease has received
    less attention than the effect of cancer. Benowitz et al. (1988)
    compared the cardiovascular effects of smokeless tobacco, cigarettes
    and nicotine gum and reported that all tobacco use increased heart
    rate and blood pressure. Nanda & Sharma (1988) recorded incremental
    increases in heart rate and blood pressure following tobacco chewing.
    However, Eliasson et al. (1991) found no significant elevation of
    diastolic blood pressure in young snuff users. Bolinder et al. (1994)
    found an excess risk of death from cardiovascular and cerebrovascular
    disease among smokeless tobacco users. Tobacco chewing has detrimental
    effects on pregnancy (Krishna, 1978) which, in the absence of any
    anoxia due to carbon monoxide found in smokers, could result from
    nicotine-induced vasoconstriction.

    O'Dell et al. (1987) reported a case of Buerger's disease in a
    38-year-old man that was associated with the use of smokeless tobacco.
    A regimen which included complete abstinence from tobacco resulted in
    a resolution of the symptoms. Buerger's disease is the commonest
    vascular disease in the Indian subcontinent where tobacco consumption
    is high (Jindal & Patel, 1992). In a study of the disease in
    Bangladesh, 39 patients (38 males, 1 female) were investigated. All
    but two were current long-term smokers, one male had given up smoking
    6 months previously and the one woman with the disease (it is uncommon
    in women) was a tobacco chewer (Grove & Stansby, 1992).
    

    3.  EFFECTS ON HEALTH OF TOBACCO USE AND EXPOSURE TO OTHER CHEMICALS

    3.1  Introduction

    3.1.1  Interaction

    To discuss the interaction between tobacco and other agents as risk
    factors for cancer and other adverse health effects, it is necessary
    to define what is meant by the term "interaction". In general terms,
    interaction represents a departure from additivity, in which the
    combined effect of exposure to two agents is in some sense the sum of
    the effects of the individual agents (US EPA, 1988). Synergism occurs
    when the combined effect is greater than the sum of the component
    effects; antagonism occurs when the effect of the combination is less
    than would be suggested by summing the effects of the components.

    3.1.2  Measuring interaction

    To make these concepts precise, the scale in which risk is measured
    and the manner in which risks are summed must be specified (Kaldor &
    L'Abbe, 1990). In epidemiological investigations, the age-adjusted
    relative risk is often used to characterize risk. In risk assessment
    applications involving chronic health effects such as cancer, the
    cumulative risk over a period of time may be of more direct interest.
    In laboratory studies of carcinogenicity, for example, the lifetime
    probability of tumour induction is often used to describe risk. In
    order to take into account the age at which an adverse effect is
    induced, the expected loss in life expectancy has also been used to
    evaluate risk (UNSCEAR, 1988).

    Kodell & Pounds (1991) discuss interaction in terms of departures from
     response additivity and  dose additivity. Dose additivity occurs
    when the combined effect of two agents can be expressed in terms of a
    total dose of the two agents, taking into account their relative
    potencies. Dose additivity presumes that the two agents act by the
    same biological mechanism, and that the effective dose of one agent is
    simply a dilution of the dose of the other agent. Response additivity
    occurs when the two agents act independently of each other. In this
    case, the probabilities of an adverse effect due to each of the agents
    can be treated as statistically independent and can be combined
    accordingly.

    The quantification of interaction may be illustrated using the
    age-specific relative risk (A,B) associated with exposure to two
    agents A and B. The relative risk is formally defined as:

              relative risk (A,B) = I(A,B)/I(0,0)

         where I(A,B) denotes the incidence rate of the disease of
         interest at a specified age in the presence of exposure and
         I(0,0) is the incidence rate in the absence of exposure. Lack of
         interaction then corresponds to additivity of the excess relative
         risk (ERR = relative risk - 1).

         Specifically,

              ERR(A,B) = ERR(A,0) + ERR(0,B)

         where ERR(A,0) and ERR(0,B) denote the excess relative risks for
         A and B alone, respectively. In terms of relative risk,
         additivity is equivalent to:

         relative risk (A,B) = relative risk (A,0) + relative risk 
         (0,B) - 1

    For a supra-additive relative risk relationship, such as the
    multiplicative relative risk model:

         relative risk (A,B) = relative risk (A,0)RR(0,B)

    and reflects a synergistic effect.

    It is of interest to note that as the relative risk (A,0) and relative
    risk (0,B) become small, the multiplicative relative risk model
    approximates the additive relative risk model. Under this 
    multiplicative model, a strong synergistic relationship may be 
    apparent at high exposures, yet become negligible at low exposures. 
    This, along with the realization that relative risks of less than 
    about two are difficult to detect epidemiologically, suggests that 
    relatively high exposures are likely to be required to evaluate 
    interactive effects reliably.

    Brown & Chu (1989) and Kodell et al. (1991) investigated the type of
    interactions that might be expected under both the Armitage-Doll
    multi-stage model and the Moolgavkar-Venzon-Knudson two-stage model of
    carcinogenesis following exposure to two carcinogens that may affect
    different stages in the model. These theoretical results indicate that
    a variety of synergistic interactions are possible, including
    supra-additive, multiplicative, and supra-multiplicative.

    Although the additive excess relative risk model described above
    provides a useful baseline for evaluating interaction, it is not the
    only model that has been proposed for this purpose. Kaldor & L'Abbe
    (1990) pointed out that the multiplicative relative risk model will
    become the baseline model for evaluating interactions following a
    logarithmic transformation of the relative risk. Thomas & Whittemore
    (1988) review arguments in favour of the additive and multiplicative
    models as the basis for evaluating interaction. Steenland & Thun
    (1986) illustrate how these two models can be applied in evaluating
    tobacco/occupation interactions in the causation of lung cancer.

    This brief overview illustrates that interaction can be measured in
    different ways, with the most appropriate depending on the nature of
    the problem at hand. In general, however, all of the commonly
    encountered measures of synergism indicate that the risk associated
    with combined exposure to two agents is in some sense greater than
    would be expected based on the risks of individual exposures. Although

    no attempt is made throughout this monograph to systematically specify
    the precise nature of the interactive effects reported in the
    literature, most interactive effects documented in this monograph have
    been identified through epidemiological investigations, in which the
    additive age-specific relative risk model is the predominant approach
    to describing interaction (Saracci, 1987; Greenland, 1993).

    There are four principal ways in which tobacco smoke can interact with
    other chemicals to impair the health of the smoker. They are not
    mutually exclusive and in fact there are many situations in which they
    may occur together, particularly in the workplace or the environs of
    industry.

    a)  Modification of effects

    Cigarette smoke can modify the harmful effects associated with other
    toxic agents, in some cases causing a highly elevated risk, e.g., the
    effects of smoking on diseases related to asbestos, alpha-radiation,
    arsenic and some organic compounds.

    b)  Increased concentration effects

    Chemical compounds hazardous to health are often found in both tobacco
    smoke and the working environment and each source can augment the dose
    obtained from the other, e.g., carbon monoxide, acrolein, benzene and
    heavy metal elements.

    c)  Vector effects

    Materials used in the workplace that produce harmful chemical agents
    when they are burnt or vaporized can contaminate smoking materials and
    cause the smoke to be far more injurious when the tobacco is smoked,
    e.g., polytetrafluoroethylene and methylparathion.

    d)  Other interactions

    Tobacco smoke can affect a physiological process and increase the
    impairment of physical or physiological functions caused by another
    activity. For instance, impaired lung clearance will affect the
    residence time of inhaled toxic materials, the effect of smoking on
    the peripheral vascular system can enhance the detrimental effects of
    vibration and noise, and smoking may alter the effect of drugs taken
    for other purposes.

    3.1.3  Effects of tobacco smoking on lung deposition and clearance of
           particles

    Pulmonary deposition of inspired particles depends on their
    physicochemical properties and on airway structure and geometry.
    Mathematical models describing the deposition of particles in the
    various airway sections show that in compromised airways, as is the
    case in patients suffering from asthma and chronic obstructive lung
    diseases, particle deposition is enhanced several-fold (ICRP, 1994).

    Tobacco smoking can be an indirect cause of enhanced deposition of
    inspirable particles. In addition, during tobacco smoking the
    breathing pattern is changed to more frequent and deeper inhalation,
    especially in the case of low-nicotine cigarettes, which can result in
    an increased inhaled dose and dose rate of inspirable compounds (IARC,
    1990).

    Clearance of particles deposited in the lung is a complex
    physiological process involving relatively rapid tracheobronchial
    clearance, in which mucus is moved upward by ciliary action to the
    pharynx and swallowed, and slower deep-lung clearance, in which
    phagocytic cells remove inhaled particles. These processes are
    balanced by the solubility of the inhaled particles, with relatively
    insoluble particles having a longer residence time in the alveolar
    portions of the lungs. A longer residence time in the lung would be
    accompanied by a greater possibility that harmful effects could occur.
    Both rapid and slow clearance phases are reduced by smoking, although
    probably by different mechanisms. Cigarette smoke contains significant
    concentrations of ciliatoxic agents, such as hydrogen cyanide,
    formaldehyde, acetaldehyde, acrolein and nitrogen oxides, which
    greatly contribute to retarded clearance of inhaled particles by
    inhibiting lung clearance mechanisms (Battista, 1976). Retardation of
    clearance has been seen for airway-deposited particles, in which
    decreased mucus transport velocities slow this normally relatively
    rapid phase of clearance (Lourenco et al., 1971; Chopra et al., 1979).

    The deep-lung clearance of relatively insoluble particles is retarded
    in smokers. Cohen et al. (1979) found that 1 year after a tracer
    particle exposure, some 50% and 10% of the original lung burden
    remained in the lungs of smokers and non-smokers, respectively.
    Bohning et al. (1982) and Philipson et al. (1996) found that smoking
    retarded long-term particle clearance from the lungs. The mechanism(s)
    for interference with this longer-term phase of clearance has not been
    shown definitively, but may be related to impairment of phagocyte
    function and/or smoke-induced lung damage.

    3.2  Interactions between tobacco smoke and other agents

    3.2.1  Asbestos

    Asbestos is a generic name for a group of fibrous silicates, differing
    in colour, fibre arrangement and length. Recognition of the health
    risks of asbestos has led to major reductions in production and uses.
    Asbestos types are classified according to their physical
    characteristics as serpentine or amphibole and differ in their
    relative carcinogenic potential. Amosite and crocidolite are
    amphiboles and have short and straight needle-like fibres. Chrysotile
    is a serpentine and consists of long, pliable white fibres. The longer
    fibre varieties of asbestos can be spun into yarn which can be woven
    into fabric; short fibre varieties can be incorporated into cement,
    asbestos board and tiles. Asbestos products have been used in a
    variety of applications including electrical and thermal insulation in
    buildings, fire and safety equipment, brake linings of motor vehicles,

    and shipbuilding. Workers in asbestos mining and processing and a wide
    range of manufacturing industries are exposed to various forms of
    asbestos, while others are exposed in maintenance work, demolition and
    recycling operations.

    Occupational exposure to asbestos is associated with asbestosis and
    cancers at various sites, notably pleural mesothelioma and lung
    cancer. Differences between the effect of asbestos on the health of
    smokers and non-smokers have been reported, and studies have been
    conducted aimed specifically at elucidating the combined effects of
    smoking and asbestos exposure. Perioccupational exposure to asbestos
    is a hazard to household contacts of asbestos workers, who bring home
    dust on their clothes, and to people living in areas where there is
    environmental contamination by asbestos dust from industry (Anderson
    et al., 1979).

    The amphibole varieties of asbestos (crocidolite and amosite) have the
    highest carcinogenic risk. Crocidolite presents a greater risk than
    amosite, which in turn is more dangerous than chrysotile, a serpentine
    variety. Erionite and tremolite are non-asbestos fibrous minerals used
    in building in some parts of the world and there is a high prevalence
    of mesothelioma in these regions (Baris et al., 1979; Yazicioglu et
    al., 1980).

    Because there are many different occupations and environmental
    situations in which asbestos exposure might occur, along with a wide
    range of possible levels of exposure and variety of types of asbestos
    in use, it is difficult to define clearly asbestos exposure or the
    smoking habits of those exposed. The smoking history of the population
    sampled is important, because there have been changes in smoking
    materials and prevalences of smoking in many countries (Cheng & Kong,
    1992). In many studies, only the number of smokers within sub-groups
    of workers with asbestos-related disease have been reported, rather
    than the detailed smoking habits of the exposed population. A widely
    used assumption is that the smoking habits of asbestos-exposed workers
    reflect those of blue collar workers and are thus higher than national
    average figures. Table 5 gives examples of smoking prevalence in
    different groups of asbestos-exposed workers.

    3.2.1.1  Asbestos and lung cancer

    Exposure to asbestos dust carries a risk of parenchymal and pleural
    fibrosis, mesothelioma and lung cancer. Selikoff et al. (1968) and
    Berry et al. (1972) showed that cigarette smoking was an added hazard
    among asbestos workers. In combination, the two hazards are associated
    with very high lung cancer rates. Studies were carried out (e.g.,
    Hammond & Selikoff, 1973; Martischnig et al., 1977; Hammond et al.,
    1979; Selikoff et al., 1980; Acheson et al., 1984; Berry et al., 1985)
    to determine whether cigarette smoke and asbestos act independently, 


        Table 5.  Smoking prevalence in asbestos-exposed workers

                                                                                                       
    Exposure                                Smoking habits                     References

                                                                                                       

    Asbestos textile workers                75% smokers                        Weiss (1971)
                                            46% cigarette smokers
                                            36% ex-cigarette smokers
                                            5.5% pipe/cigar smokers

    Electrochemical plant                   84% to 87% were smokers
    (two areas)                             or ex-smokers                      Kobusch et al. (1984)

    Population in Telemark,                 Asbestos exposed:                  Hilt (1986)
    Norway                                  44.6% smokers
                                            36.0% ex-smokers
                                            Not exposed:
                                            40.95% smokers
                                            28.6% ex-smokers

    Survey of 800 000 American              Asbestos exposed:                  Stellman et al.  (1988)
    men and women in 1982                   33.6% smokers
                                            47.3% ex-smokers

    Lung cancer case-referent               Men: 95% smokers                   Järvholm (1993)
    study; Swedish industrial city          Women: 78% smokers

    Shipyard workers in                     46% smokers                        Sanden et al. (1992)
    Gothenburg, Sweden                      31% ex-smokers
    December 1987                           21% non-smokers
                                            2% not known

    Asbestos factory workers                Men: 74% smokers                   Newhouse & Berry (1979)
                                            (male population average 66%)
                                            Women: 49% smokers
                                            (female population average 40%)
                                                                                                       
    

    their combined effect being the sum of the individual effects, or
    there is an interaction with the ultimate effect being a product of
    the two risk factors. In some studies, the effects of smoke and
    asbestos appeared to be additive, in others multiplicative and in
    others somewhere between the two. Reasons for the lack of consistency
    among the studies may relate to the size of the population sampled,
    its average age, social class and residential area, the type of
    asbestos involved, the time scale covered and the intensity of
    exposure to asbestos. The weight of evidence favours a synergistic or
    multiplicative model for the interaction of asbestos and smoking.
    While the differences may be partly linked to the carcinogenic
    potential of different types of asbestos and to different smoking
    materials and ways of smoking, including passive smoking (Cheng &
    Kong, 1992), they also reflect the complex nature of tobacco smoke,
    which contains complete carcinogens, tumour promoters and
    co-carcinogens and other compounds that can influence the multistage
    carcinogenic process. However, whatever the type of smoking/asbestos
    interaction influencing the incidence of lung cancer, there is a
    greatly increased risk for the asbestos-exposed worker who smokes
    (Table 6).

    Hammond et al. (1979) found a very strong synergistic effect and this
    was supported by studies of shipyard workers in Italy (Bovenzi et al.,
    1993), asbestos factory workers in London (Newhouse & Berry, 1979),
    Finnish anthophyllite miners and millers (Meurman et al., 1979),
    chrysotile workers in China (Cheng & Kong, 1992; Zhu & Wang, 1993) and
    workers exposed to crocidolite in Western Australia (de Klerk et al.,
    1991). Cheng & Kong (1992) reported a lower ratio of non-smoking to
    smoking lung cancer death rates and suggested that this reflected
    passive smoking among non-smokers and the use by most smokers of
    hand-rolled cigarettes. Liddell et al. (1984) found that their data
    fitted both an additive model and a multiplicative model and concluded
    that the combined relative risk lay somewhere between the two.
    Selikoff et al. (1980), from a study of amosite factory workers, and
    Berry et al. (1985), from a study of asbestos factory workers,
    favoured an additive model. However, caution is required because of
    the definitions of additive and multiplicative used by different
    authors and the overlap between these terms and such words as
    synergism and promoter.

    Molecular biology studies of autopsy specimens of lung tumour tissue
    from of cigarette smokers have revealed that cigarette smoking induces
    K-ras mutation (Rodenhuis & Slebos, 1992). It has been suggested that
    such cigarette-smoke-induced K-ras oncogene mutations are promoted by
    the presence of asbestos, which creates selective growth conditions
    for the mutated cells (Vainio et al., 1993). Vainio & Boffetta (1994)
    concluded that both tobacco smoke and asbestos fibres can be genotoxic
    and cytotoxic, and cause proliferative lesions in the lungs. Tobacco
    smoke contains carcinogens that bind to critical genes and cause
    mutations. Asbestos fibres cause chronic inflammation of the lungs,
    which releases various cytokines and growth factors, and may provide a
    selective growth advantage for mutated cells.


        Table 6.  Age-standardized lung cancer death ratesa for cigarette smoking and/or 
    occupational exposure to asbestos dust compared with no smoking and no occupational
    exposure to asbestos dust (from: Hammond et al., 1979)
                                                                                         

    Group                Exposure to   History cigarette  Death   Mortality   Mortality
                         asbestos?     smoking?           rate    difference  ratio

                                                                                         

    Control              No            No                 1.3     0.0         1.00

    Asbestos workers     Yes           No                 58.4    +47.1       5.17

    Control              No            Yes                122.6   +111.3      10.85

    Asbestos workers     Yes           Yes                601.6   +590.3      53.24
                                                                                         

    a  Rate per 100 000 man-years standardized for age on the distribution of the
       man-years of all the asbestos workers; number of lung cancer deaths based on
       death certificate information
    

    3.2.1.2  Asbestos and pleural mesothelioma

    There is an established relationship between exposure to asbestos 
    - crocidolite, amosite, chrysotile - and pleural mesothelioma
    (Stellman, 1988). In shipyard workers mainly exposed to chrysotile,
    Sanden et al. (1992) found an increase in pleural mesotheliomas up to
    15 years after cessation of exposure. Asbestos is also linked with
    peritoneal mesothelioma (Newhouse & Berry, 1976). The risk of lung
    cancer was found to fall after exposure ceased, suggesting that
    asbestos acted as a lung cancer promoter, but the risk of mesothelioma
    long after cessation of exposure indicated that asbestos acted as a
    complete carcinogen. Mesothelioma can have an extremely long latent
    period, with cases presenting even 30 years or more after first
    exposure (Newhouse & Berry, 1976). Up to 90% of cases of pleural
    mesothelioma have been attributed to asbestos but there is no evidence
    directly associating smoking with the disease, or showing that smoking
    has any influence on the incidence of asbestos-related pleural
    mesothelioma (Berry et al., 1985; Hughes & Weill, 1991; Sanden &
    Jarvholm, 1991; Muscat & Wynder, 1991).

    3.2.1.3  Asbestos and other forms of cancer

    Asbestos fibres have been found in many tissues, other than the lungs,
    of asbestos workers. There is evidence that an asbestos/smoking
    interaction increases the incidence of cancer of the oesophagus,
    pharynx, buccal cavity and larynx but not of pleural or peritoneal
    mesothelioma, or of cancer of the stomach, colon-rectum or kidney, for
    which smoking and non-smoking asbestos workers are at equal risk
    (Hammond et al., 1979; Selikoff & Frank, 1983; US ATSDR, 1995).

    3.2.1.4  Asbestosis

    Asbestosis is a fibrotic reaction to asbestos in the lungs. In a
    review of histological, animal experimental and radiological evidence,
    Weiss (1984) concluded that cigarette smoking could result in diffuse
    fibrosis similar to that caused by asbestos, and the fibrosis showed a
    dose-response to the duration and degree of smoking. Prevalence
    studies are consistent in showing a higher frequency of diffuse small
    irregular opacities in asbestos workers who are smokers than in those
    who are non-smokers. It has been suggested that the effects may be
    additive. Tobacco smoke affects lung clearance and hence the retention
    of asbestos fibres in the lungs. In asbestosis the intensity of
    fibrosis correlates with the number of asbestos bodies in the lungs,
    and Murai et al. (1994) concluded that reduction of lung clearance by
    tobacco smoke could increase the intensity of fibrosis. Crocidolite
    fibres are the most fibrogenic of the various types of asbestos but
    De Klerk et al. (1991) concluded that smoking had no measurable effect
    on crocidolite asbestosis.

    An interaction between asbestos and smoking causing a greater
    frequency of obstructive airways disease in asbestos workers who smoke
    was found in a study of pulmonary function changes caused by
    asbestosis (Selikoff & Frank, 1983). Miller (1993) presented similar

    results suggesting an interaction between asbestos and smoking. In a
    prospective mortality study, Hughes & Weill (1991) concluded that
    asbestosis is a precursor of asbestos-related lung cancer, but they
    were unable to assess an interaction between tobacco smoking and
    asbestosis because all the cases were in smokers and there were no
    non-smokers.

    In rats, asbestos fibres stimulate alveolar macrophages to generate
    the inflammatory and fibrogenic mediators, tumour necrosis
    factor-alpha (TNF-alpha), and this may be the cause of inflammation 
    and lung fibrosis due to asbestos (Ljungman et al., 1994). In  in vitro
    studies Morimoto et al. (1993) found synergism between chrysotile
    fibres and cigarette smoke in the stimulation of the formation of
    TNF-alpha b